Summary & Overview
HCPCS G9652: Systemic or Biologic Treatment for Psoriasis, ≥6 Months
HCPCS Level II code G9652 documents that a patient has received systemic or biologic therapy for psoriasis for at least six months. Nationally, this code matters because it standardizes documentation of ongoing immunomodulatory treatment for a chronic dermatologic condition, informing coverage decisions, quality measurement, and care coordination across outpatient dermatology and infusion settings.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for G9652, how the code is used within service lines that manage systemic and biologic therapies, and what to expect in payer coverage conversations. The publication also outlines typical sites of service and the administrative role of the code in treatment-history documentation.
The report provides benchmarks and policy-relevant notes where available, summarizes clinical context for use of systemic and biologic psoriasis therapies, and identifies areas where additional coding or documentation may be required by payers. Data not provided in the input are noted as unavailable; the focus remains on national applicability rather than state-level rules.
Billing Code Overview
HCPCS Level II code G9652 indicates that a patient has been treated with a systemic or biologic medication for psoriasis for at least six months. This code documents ongoing systemic or biologic therapy for psoriasis and is used to capture treatment history rather than a specific procedure.
-
Service type: Ongoing systemic or biologic medication management for psoriasis
-
Typical site of service: Dermatology clinic or outpatient specialty infusion/administration center
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 42-year-old patient with chronic plaque psoriasis has been treated with a systemic biologic agent (for example, a TNF inhibitor or IL-17/IL-23 pathway biologic) for at least six months. The patient presents to a dermatology infusion clinic or specialty pharmacy clinic for routine follow-up to assess efficacy, adverse effects, and ongoing need for therapy. The clinical workflow includes review of medication adherence, documentation of Psoriasis Area and Severity Index (PASI) or physician global assessment, screening for infections or laboratory abnormalities, ordering routine baseline and monitoring labs (CBC, CMP, hepatitis panel, TB test as indicated), and coordinating medication refill or infusion/administration scheduling. Typical encounters occur in an outpatient dermatology clinic, specialty infusion center, or ambulatory infusion suite, and may involve dermatologists, nurse practitioners, physician assistants, specialty pharmacists, and infusion nurses. Clinical documentation confirms continuous systemic or biologic therapy for at least six months to support billing under G9652 and includes medication name, start date, dosing, clinical response, and any adverse events.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable E/M service by the same physician on the same day of a procedure | Use when a distinct evaluation and management visit is performed in addition to a procedure or infusion-related service. |